Navigation Links
PET tracer changes management plan for brain tumor patients
Date:3/1/2012

Reston, Va. (March 1, 2012) Imaging amino acid transporters with positron emission tomography/computed tomography (PET/CT) has been shown to significantly alter intended management plans for patients with brain tumors, according to research in the March issue of The Journal of Nuclear Medicine. As a result of imaging with the radiopharmaceutical 3,4-dihydroxy-6-F-18-fluoro-L-phenylalanine (F-18-DOPA), physicians changed the intended management plan for 41 percent of patients with brain tumors.

Contrast-enhanced magnetic resonance imaging (MRI) is most frequently used to diagnose and monitor patients with brain tumors. After initial treatment, however, the assessment of recurrence by MRI can be difficult since contrast enhancement cannot reliably distinguish tumor recurrence from radiation necrosis. PET/CT imaging provides a highly accurate image that is beneficial for detecting primary and recurrent high- and low-grade brain tumors.

In the study, "Impact of 3,4-Dihydroxy-6-F-18-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective," referring physicians were given a survey prior to performing PET/CT scans with F-18-DOPA on patients with known or suspected brain tumors. The pre-scan surveys asked about indication, tumor histology or grade, level of suspicion for tumor recurrence and planned management. Soon after the PET/CT scans, the referring physicians were asked to complete a survey to categorize PET findings, level of suspicion for primary or recurrent brain tumors and intended management changes. Six months following the scans, the physicians took another survey dealing with recurrence and survival.

Of the 58 cases that were included in the survey, the clinical suspicion for recurrence increased in 33 percent, remained unchanged in 50 percent and decreased in 17 percent of patients after adding the PET/CT findings to other diagnostic data. As a result, several changes in management were recommended, with changes from "watch and wait" to chemotherapy (25 percent) and from chemotherapy to "watch and wait" (17 percent) occurring most frequently. Seventy-five percent of the recommended changes were implemented.

"We know that F-DOPA PET/CT imaging is highly accurate for detecting brain tumors, and in our research we've shown that this imaging modality has a significant impact on patient management," said Johannes Czernin, MD, one of the authors of the study. "In the future, we will initiate multicenter trials to determine whether these management changes have an impact on patient outcome. We believe that amino-acid transport imaging with PET will eventually be an important and frequently used imaging modality in brain cancer."

According to the American Brain Tumor Association, an estimated 64,530 new cases of primary brain tumors were expected to be diagnosed last year. It is estimated that during the year 2004 more than 612,000 people in the United States were living with the diagnosis of a primary brain or central nervous system tumor. The five year survival rates vary among tumor subtypes and range from 3.3 percent for high-grade tumors to 70 percent for low-grade tumors.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
2. Novel radiotracer shines new light on the brains of Alzheimers disease patients
3. Physical Changes in Brain Linked to Altered Spirituality
4. Northern California Cancer Center Changes Name to Cancer Prevention Institute of California
5. Medicare Advantage Members May Make Changes During Open Enrollment
6. CMS Watch Changes Name to The Real Story Group
7. Changes during menopause increases risk of heart disease and stroke
8. Childhood stress such as abuse or emotional neglect can result in structural brain changes
9. Dmatek Changes its Name to Attenti
10. Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers
11. YourHCG.com Changes the Way People Lose Weight by Offering an Affordable HCG Diet Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Mobility Designed ... put pressure on the armpits, the M+D Crutch evenly distributes body weight from the ... wrists and hands when using the crutches than with other crutches. , Co-founders Max ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed ... an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show ... Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and development and ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology: